What is Lifesci Capital’s Estimate for ELDN FY2024 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Lifesci Capital upped their FY2024 earnings per share estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.47). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($1.52) per share. Lifesci Capital also issued estimates for Eledon Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ:ELDN opened at $4.00 on Friday. Eledon Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $5.54. The firm has a market capitalization of $158.62 million, a price-to-earnings ratio of -1.99 and a beta of 0.76. The business’s 50 day simple moving average is $3.26 and its 200-day simple moving average is $2.89.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ELDN. Marco Investment Management LLC increased its holdings in Eledon Pharmaceuticals by 22.3% during the 2nd quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock valued at $80,000 after acquiring an additional 5,535 shares in the last quarter. Clarity Capital Partners LLC purchased a new position in shares of Eledon Pharmaceuticals during the 3rd quarter worth approximately $29,000. CM Management LLC increased its stake in shares of Eledon Pharmaceuticals by 14.3% during the 1st quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $330,000 after purchasing an additional 20,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Eledon Pharmaceuticals during the 2nd quarter worth approximately $80,000. Finally, Armistice Capital LLC lifted its position in shares of Eledon Pharmaceuticals by 1.7% in the second quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock valued at $6,167,000 after acquiring an additional 39,000 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).